
GSK’s asthma drug wins FDA approval to treat ’smoker’s lung’
By Siddhi Mahatole and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration has approved British drugmaker GSK’s asthma drug to treat some patients with a chronic lung disease commonly known as "smoker’s lung", the company said on Thursday. The approval expands the use of the drug, Nucala, as an add-on treatment for patients with a type of chronic obstructive pulmonary disease. Sanof ...